Cwm LLC Decreases Stock Holdings in Bruker Corporation $BRKR

Cwm LLC lessened its holdings in Bruker Corporation (NASDAQ:BRKR) by 98.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,089 shares of the medical research company’s stock after selling 55,842 shares during the quarter. Cwm LLC’s holdings in Bruker were worth $35,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Pacer Advisors Inc. purchased a new position in shares of Bruker in the 3rd quarter valued at about $474,000. Thrivent Financial for Lutherans increased its stake in Bruker by 11.9% in the second quarter. Thrivent Financial for Lutherans now owns 29,032 shares of the medical research company’s stock valued at $1,196,000 after purchasing an additional 3,085 shares during the last quarter. Advisory Services Network LLC raised its holdings in Bruker by 35.9% during the second quarter. Advisory Services Network LLC now owns 9,535 shares of the medical research company’s stock worth $366,000 after purchasing an additional 2,520 shares in the last quarter. FORA Capital LLC lifted its position in shares of Bruker by 94.1% during the 2nd quarter. FORA Capital LLC now owns 21,239 shares of the medical research company’s stock worth $875,000 after buying an additional 10,294 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Bruker by 56.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock valued at $172,000 after buying an additional 1,497 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. This represents a 5.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John A. Ornell sold 6,233 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the transaction, the director directly owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 15,233 shares of company stock worth $726,487. Corporate insiders own 27.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on BRKR shares. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research note on Wednesday, December 10th. Citigroup lifted their target price on Bruker from $40.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 16th. Rothschild Redb raised Bruker to a “strong-buy” rating in a research report on Thursday, November 20th. Wells Fargo & Company lifted their price target on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, Barclays boosted their price objective on Bruker from $45.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.36.

Bruker Stock Up 4.2%

Shares of NASDAQ:BRKR opened at $51.95 on Thursday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $61.01. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. The firm’s 50-day simple moving average is $47.70 and its 200-day simple moving average is $40.20. The company has a market cap of $7.89 billion, a price-to-earnings ratio of -324.69, a PEG ratio of 6.55 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same quarter last year, the firm earned $0.60 earnings per share. The firm’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Monday, December 8th. Bruker’s payout ratio is presently -125.00%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.